Provention Bio Inc (PRVB)
8.77
+0.06 (+0.69%)
USD |
NASDAQ |
Jan 27, 16:00
8.76
-0.01 (-0.11%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 764.66M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 157.9% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 215.11 |
| Price to Book Value | 5.282 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.1609 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
PR Newswire
01/05 16:01
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/24/2023* | 08:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/24/2023* | -- | Results | Q4 2022 | -- | -0.32 | -- | |
| 11/03/2022 | 08:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/03/2022 | -- | Results | Q3 2022 | -0.34 | -0.42 | 19.05% | |
| 08/04/2022 | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q2 2022 | -0.46 | -0.50 | 7.38% | |
| 05/05/2022 | 08:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 05/05/2022 | -- | Results | Q1 2022 | -0.35 | -0.47 | 24.73% |
*Estimated Date/Time
Earnings
Profile
Edit
| Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-6527, PRV-300, and PRV-101. |
| URL | https://www.proventionbio.com |
| Investor Relations URL | https://investors.proventionbio.com/ |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 24, 2023 (est.) |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of January 27, 2023.
Fundamentals
| Revenue (TTM) | 2.799M |
| Total Expenses (TTM) | 116.65M |
| Net Income (TTM) | -106.12M |
| Total Assets (Quarterly) | 193.91M |
| Total Liabilities (Quarterly) | 49.14M |
| Shareholders Equity (Quarterly) | 144.77M |
| Cash from Operations (TTM) | -90.89M |
| Cash from Investing (TTM) | -74.55M |
| Cash from Financing (TTM) | 128.48M |
Ratings
Profile
Edit
| Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-6527, PRV-300, and PRV-101. |
| URL | https://www.proventionbio.com |
| Investor Relations URL | https://investors.proventionbio.com/ |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 24, 2023 (est.) |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| PRVB Tweets |